Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...
UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year...
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...
Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...
Merck & Co. (NYSE: MRK) has released its Q4 and full-year 2022 financial report, showcasing...
Japan-based pharmaceutical giant Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that sales of...
China-based Zhejiang Gongdong Medical Technology Co., Ltd is set to acquire core assets of US...
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
China-based high-end interventional device maker Shanghai Weimu Medical Technology Co., Ltd has reportedly raised “tens...
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB...
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the conclusion of a Phase I...
Eli Lilly & Co. (NYSE: LLY) reported its Q4 2022 financials, revealing a 9% year-on-year...
US-based Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) has announced the engagement of advisors to help search...
Denmark-based diabetes giant Novo Nordisk (NYSE: NVO) has reported financial results for the fourth quarter...
China-based Antengene Corporation Ltd (HKG: 6996) has received approval from Australia’s Therapeutic Goods Administration (TGA)...
Shanghai Henlius Biotech (HKG: 2696) has announced the dosing of the first subject in a...
Sino-US biotech firm NeuShen Therapeutics Inc., focused on central nervous system (CNS) disorders, has announced...